The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin

Biochemical Pharmacology

Volumn 62, Issue 5, 2001, Pages 561-567

  Loetchutinat, Chatchanok ^a   Heywang, Christine ^a   Priebe, Waldemar ^b   Garnier Suillerot, Arlette ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Daunorubicin; Enantiomer; MRP1; P glycoprotein

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG; WP 900;

ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOSOL; DRUG ACCUMULATION; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; ENANTIOMER; ERYTHROLEUKEMIA CELL; FLUORESCENCE; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOCHEMISTRY;

ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CYTOSOL; DAUNORUBICIN; DNA; DRUG RESISTANCE; HUMANS; K562 CELLS; MOLECULAR CONFORMATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0035452217     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00703-1     Document Type: Article

References (33)

1. Mechanism of multidrug resistance
2. Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line
3. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
4. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
5. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
6. ABC transporters - From microorganisms to man
7. Impaired accumulation of drug in multidrug resistance cells. What are the respective contributions of the kinetics of uptake and of P-glycoprotein-mediated efflux of drug?
8. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells
9. Mechanism of action-governed design of anthracycline antibiotics: A "turn-off/turn-on" approach
10. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity
11. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
12. Modulators of P-glycoprotein-associated multidrug resistance
13. Mutually cooperative interactions between modulators of P-glycoprotein
14. Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition
15. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement
16. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
17. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein
18. Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors
19. Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype
20. Absorption enhancement of hydrophilic compounds by verapamil in Caco-2 cell monolayers
21. The absence of stereo selective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum
22. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line
23. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells
24. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells
25. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents
26. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line
27. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and-sensitive K562 cells
28. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells
29. P-glycoprotein mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells
30. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells
31. Bafilomycins: A class of inhibitors of membrane ATPases from microorganisms, animal cells and plant cells
32. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases
33. Multidrug resistance protein functionality: No effect of intracellular or extracellular pH changes